TLT.V - Theralase Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.385
+0.010 (+2.67%)
At close: 2:19PM EDT
Stock chart is not supported by your current browser
Previous Close0.375
Open0.390
Bid0.380 x 0
Ask0.385 x 0
Day's Range0.375 - 0.390
52 Week Range0.190 - 0.550
Volume71,130
Avg. Volume363,517
Market Cap50.661M
Beta0.39
PE Ratio (TTM)N/A
EPS (TTM)-0.044
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.38
  • FSCWire6 days ago

    Theralase Achieves Exploratory Efficacy Endpoint in Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study for Patients Five and Six

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has provided an update on patient six, enrolled and treated in the recently completed Phase Ib NMIBC clinical study (“Study”). The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy.

  • FSCWire24 days ago

    Theralase Release 2Q2018 Financial Statements

    Toronto, Ontario (FSCwire) - (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy cancer released its 2Q2018 financial statements. In the US, revenue decreased 13% to $183,460 from $211,453 and international revenue increased 252% to $124,953 from $35,441. The increase in international revenue in 2018 and the corresponding decrease in Canadian and US revenue is attributable to the Company hiring an International Sales Manager and restructuring the Canadian and US sales and marketing departments.

  • Newsfile24 days ago

    BTV Reveals Novel Cancer Treatment, Cannabis and Lithium Companies

    Vancouver, British Columbia--(Newsfile Corp. - July 26, 2018) - On BNN Sat July 28 & Sun July 29, 2018 - BTV-Business Television goes on location with four small cap companies in popular sectors. Full EpisodeBlissCo Cannabis Corp. (CSE: BLIS) — BTV shares how this CEO's distribution background will help his company profit in the rapidly expanding cannabis market. See Feature  Critical Elements Corp. (TSXV: CRE) (OTCQX: CRECF) — Electric vehicle demand spells opportunity for the key ...

  • FSCWirelast month

    Theralase Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has provided an update on patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”). The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy.

  • FSCWire2 months ago

    Theralase Releases AGM Videos

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical-stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations used to safely and effectively destroy cancer is pleased to announce the release of three videos presented at the completion of the Company’s Annual and Special Meeting, held at the Company’s corporate office on June 22, 2018.

  • FSCWire2 months ago

    Theralase Researchers Receive Government Grant

    Theralase Researchers Receive Government Grant Toronto, Ontario (FSCwire) - Theralase Technologies Inc. ...

  • FSCWire2 months ago

    Theralase Strengthens Its Patent Portfolio with an Additional US Patent Covering Metal-Glycoprotein Complexes, Including Rutherrin(R) Based Photo Dynamic Therapy, in Immune Privileged Sites

    Theralase Strengthens Its Patent Portfolio with an Additional US Patent Covering Metal-Glycoprotein Complexes, Including Rutherrin® Based Photo Dynamic Therapy, in Immune Privileged Sites

  • Theralase(R) Demonstrates Significant Advantage in Treatment of Brain Tumours
    FSCWire2 months ago

    Theralase(R) Demonstrates Significant Advantage in Treatment of Brain Tumours

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, intended to safely and effectively destroy cancer, has announced significant benefits of its Rutherrin® (TLD-1433 + transferrin) formulation in comparison to a clinically approved PDC Amino Levulinic Acid (“ALA”), in the destruction of Rat Glioma (“RG2”)  brain tumours, representative of GlioBlastoma Multiforme (“GBM”), a deadly form of human brain cancer. As previously disclosed, Theralase demonstrated that rats subjected to RG2 cancer cells, developed brain tumours representative of GBM.

  • FSCWire2 months ago

    Theralase Demonstrates 36 Months Stability of Lead Anti-Cancer Drug

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy cancer has announced today that it has demonstrated 36 months long term stability of the clinical batch of its lead anti-cancer PDC, TLD-1433. The confirmation of 36 months long term stability of TLD-1433 ensures that sufficient amounts of the PDC will be available at Good Manufacturing Practice (“GMP”) levels for multiple Photo Dynamic Therapy (“PDT”) patient treatments during the planned Phase 2 clinical study for Non-Muscle Invasive Bladder Cancer (“NMIBC”).

  • FSCWire3 months ago

    Theralase Release 1Q2018 Financial Statements

    Toronto, Ontario (FSCwire) - (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy cancer released its 1Q2018 financial statements. In the US, revenue decreased 36% to $90,354 from $141,714 and international revenue increased 23% to $53,778 from $43,528. The increase in international revenue in 2018 and the corresponding decrease in Canadian and US revenue is attributable to the Company focusing it’s sales and marketing efforts on the Canadian and international markets.

  • FSCWire3 months ago

    Theralase Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study

    Theralase Medical and Scientific Advisory Board concluded that the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) has met its objectives and unanimously voted for the early termination of the Study based on successfully achieving its primary and secondary endpoints after six patients.

  • FSCWire3 months ago

    Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers provides an update on the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) currently in progress. The Study is being used to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy.

  • FSCWire4 months ago

    Theralase Increases Revenue 22% for 2017 Financial Statements

    In the US, revenue decreased 37% to $261,833 from $416,812 while, international revenue increased 76% to $138,665 from $78,900. The increase in Canadian and international revenue in 2017 and the corresponding decrease in US revenue is attributable to the Company’s sales and marketing team focusing on the Canadian and international markets.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Eyecarrot Innovations, Antibe Therapeutics, Emblem and Theralase Technologies

    NEW YORK, NY / ACCESSWIRE / April 20, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE4 months ago

    Canadian Exchanges Stock Scanner Titan Medical, Patient Home Monitoring, Zecotek Photonics, and Theralase Technologies

    LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Medical Devices industry: Titan Medical, Patient Home Monitoring, Zecotek Photonics, and Theralase Technologies. The TSX Venture Exchange gained 5.05 points, or 0.63%, to finish at 802.60. Today's stocks of interest consist of: Titan Medical Inc. (TSX: TMD), Patient Home Monitoring Corporation (TSX-V: PHM), Zecotek Photonics Inc. (TSX-V: ZMS), and Theralase Technologies Inc. (TSX-V: TLT).

  • FSCWire4 months ago

    Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer (NMIBC) Clinical Study

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers, provides an update on the Phase Ib NMBIC clinical study (“Study”) currently in progress. The Study is being used to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy.

  • Baystreet4 months ago

    Medical Technology Advancements Spur New Opportunity For Investment

    The U.S. health care market is the largest in the world by market size. Health Access reports that ...

  • Theralase Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer
    FSCWire5 months ago

    Theralase Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers, announced the filing of a US patent application detailing the discovery of a significant increase in the destruction of cancer cells, when Theralase’s patented anti-cancer technology is combined with cannabinoids. In preclinical experiments, Theralase scientific researchers combined a specific cannabinoid with their patented anti-cancer Photo Dynamic Therapy (“PDT”) technology to produce an unexpected synergistic effect in the destruction of rat glioma brain cancer cells (“RG2”).

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Emblem, 3D Signatures, ABcann Global and Theralase Technologies Inc.

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells
    FSCWire5 months ago

    Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers, announced today that its lead PDC, TLD-1433, combined with transferrin to form Rutherrin®, has been demonstrated to effectively destroy human brain cancer stem cells. Despite tremendous advances in cancer therapy over the last ten years, resistance to treatment and high rates of recurrence remain stubbornly common.

  • FSCWire5 months ago

    Rutherrin(R) Technology Granted Allowance for Canadian Patent

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF),  a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers, announced today that it has been notified that it has been granted allowance for a Canadian patent to issue later this year for Rutherrin® (TLD-1433 PDC combined with transferrin) for the treatment of cancer. “Allowance of one of the Company’s key patents is timely as we approach the completion of enrollment in our Phase Ib trial for Non-Muscle Invasive Bladder Cancer (“NMIBC”).

  • FSCWire6 months ago

    Theralase Announces Settlement Agreement with Ontario Securities Commission

    Theralase Technologies Inc. (the “Company”) (TSXV: TLT) (OTCQX: TLTFF) announced today that the Company and Roger Dumoulin-White, former Chairman, President and Chief Executive Officer, have entered into a settlement agreement (“Agreement”) with Staff of the Ontario Securities Commission (“OSC”).

  • FSCWire6 months ago

    Theralase Anti-Cancer Technology Treats Sixth Patient for Bladder Cancer

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTCQX), a clinical stage pharmaceutical company dedicated to the research and development of patented, light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations for the safe and effective destruction of various cancers, announced today that the sixth patient in a nine patient Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) was enrolled and treated on February 7, 2018, using the Company’s anti-cancer technology. The Study is being used to evaluate the Company’s lead PDC drug for the primary endpoint of safety and tolerability with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue).

  • FSCWire7 months ago

    Correcting and Replacing: Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

    January 18, 2018, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and when used in conjunction with Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fifth patient in a Phase Ib Non-Muscle Invasive Bladder (“NMIBC”) clinical study (“Study”) was enrolled and treated on January 10, 2018, using the Company’s anti-cancer Photo Dynamic Therapy (“PDT”) technology. The anti-cancer PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow the PDC to be preferentially absorbed by NMIBC tumours.

  • FSCWire7 months ago

    Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

    Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and when used in conjunction with Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fifth patient in a Phase Ib Non-Muscle Invasive Bladder (“NMIBC”) clinical study (“Study”) was enrolled and treated on January 11, 2017, using the Company’s anti-cancer Photo Dynamic Therapy (“PDT”) technology. The anti-cancer PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow the PDC to be preferentially absorbed by NMIBC tumours.